3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Malignant Solid Neoplasm
1
Inflammatory Breast Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Bladder Urothelial Carcinoma
1
Advanced Breast Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
vandetanib
7
Sorafenib
6
Magnetic Resonance Spectroscopy
6
lenvatinib
5
cabozantinib
5
Sunitinib
4
Iodine-131
4
selpercatinib
3
AZD 6244
3
trametinib
2
tipifarnib
2
durvalumab
2
dabrafenib
2
alectinib
2
Triiodothyronine
2
Thyroxine
2
Thyrotropin Alfa
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Everolimus
2
Bortezomib
2
Axitinib
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
tremelimumab
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Neoplasms
×
trastuzumab biosimilar HLX02
×
Clear all
No trials found.